RT Journal Article
SR Electronic
T1 Association of antihypertensive agents with the risk of in-hospital death in patients with Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.23.20237362
DO 10.1101/2020.11.23.20237362
A1 Chouchana, Laurent
A1 Beeker, Nathanaël
A1 Garcelon, Nicolas
A1 Rance, Bastien
A1 Paris, Nicolas
A1 Salamanca, Elisa
A1 Polard, Elisabeth
A1 Burgun, Anita
A1 Treluyer, Jean-Marc
A1 Neuraz, Antoine
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/24/2020.11.23.20237362.abstract
AB In this retrospective multicenter cohort study, we aimed to investigate the association between antihypertensive agent exposure and in-hospital mortality in patients with Covid-19. Of 8,078 hospitalized patients for Covid-19, 3,686 (45.6%) had hypertension including 2043 (55.4%) patients exposed to a renin-angiotensin-aldosterone inhibitors (RAASi), 1624 (44.1%) to calcium channel blockers (CCB) and 1154 (37.7%) to beta-blockers. Overall in-hospital 30-day mortality was 23.1%. Compared to non-users, the risk of mortality was lower in CCB (aOR, 0.83 [0.70-0.99]) and beta-blockers users (aOR, 0.80 [0.67-0.95]), and not different in RAASi users. These findings support the continuation of antihypertensive agents in patients with Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by State funding from The French National Research Agency (ANR) under "Investissements d'Avenir" programs (Reference: ANR-10-IAHU-01) and ANR PractikPharma grant (ANR-15-CE23-0028).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the AP-HP Health Data Warehouse approved this study on April 7th, 2020 (CSE-20-18_COVID19)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request. The data underlying this article will be shared on reasonable request to the corresponding author.